Defence Therapeutics Inc. (DTC) - Net Assets
Based on the latest financial reports, Defence Therapeutics Inc. (DTC) has net assets worth €-1.22 Million EUR (≈ $-1.43 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.37 Million ≈ $1.60 Million USD) and total liabilities (€2.59 Million ≈ $3.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read DTC total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.22 Million |
| % of Total Assets | -89.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 214.45 |
Defence Therapeutics Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Defence Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore total assets of Defence Therapeutics Inc. for the complete picture of this company's asset base.
Annual Net Assets for Defence Therapeutics Inc. (2020–2024)
The table below shows the annual net assets of Defence Therapeutics Inc. from 2020 to 2024. For live valuation and market cap data, see market cap of Defence Therapeutics Inc..
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | €-3.58 Million ≈ $-4.19 Million |
-328.85% |
| 2023-06-30 | €1.57 Million ≈ $1.83 Million |
+504.11% |
| 2022-06-30 | €-387.56K ≈ $-453.10K |
-107.06% |
| 2021-06-30 | €5.49 Million ≈ $6.41 Million |
+194.43% |
| 2020-06-30 | €1.86 Million ≈ $2.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Defence Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2913473300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €26.22 Million | % |
| Total Equity | €-3.58 Million | 100.00% |
Defence Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Defence Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Polylite Taiwan Co Ltd
TWO:1813
|
$18.07 Million |
|
Bukit Jalil Global Acquisition 1 Ltd. Ordinary Shares
NASDAQ:BUJA
|
$18.09 Million |
|
Conifer Holding Inc
NASDAQ:CNFR
|
$18.09 Million |
|
Seouleaguer Co. Ltd
KQ:043710
|
$18.10 Million |
|
Alpha Microelectronics
TWO:8024
|
$18.07 Million |
|
Blue Sky Uranium Corp
V:BSK
|
$18.06 Million |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
$18.06 Million |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
$18.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Defence Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,566,167 to -3,584,228, a change of -5,150,395 (-328.9%).
- Net loss of 13,193,045 reduced equity.
- New share issuances of 1,889,250 increased equity.
- Other factors increased equity by 6,153,400.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.19 Million | -368.09% |
| Share Issuances | €1.89 Million | +52.71% |
| Other Changes | €6.15 Million | +171.68% |
| Total Change | €- | -328.85% |
Book Value vs Market Value Analysis
This analysis compares Defence Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | €0.05 | €0.33 | x |
| 2021-06-30 | €0.16 | €0.33 | x |
| 2022-06-30 | €-0.01 | €0.33 | x |
| 2023-06-30 | €0.04 | €0.33 | x |
| 2024-06-30 | €-0.08 | €0.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Defence Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-104.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -36.12% | 0.00% | 0.00x | 1.03x | €-859.54K |
| 2021 | -52.11% | 0.00% | 0.00x | 1.02x | €-3.41 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | €-7.31 Million |
| 2023 | -431.80% | 0.00% | 0.00x | 2.26x | €-6.92 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-12.83 Million |
Industry Comparison
This section compares Defence Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Defence Therapeutics Inc. (DTC) | €-1.22 Million | -36.12% | N/A | $18.07 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About Defence Therapeutics Inc.
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting vario… Read more